Alterity Therapeutics Limited (ATHE)
NASDAQ: ATHE · Real-Time Price · USD
4.080
-0.110 (-2.63%)
Feb 21, 2025, 4:00 PM EST - Market closed
Alterity Therapeutics Employees
Alterity Therapeutics had 10 employees as of June 30, 2024. The number of employees decreased by 1 or -9.09% compared to the previous year.
Employees
10
Change (1Y)
-1
Growth (1Y)
-9.09%
Revenue / Employee
$268,167
Profits / Employee
-$1,275,918
Market Cap
38.51M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
ATHE News
- 12 days ago - Alterity Therapeutics Raises A$40.0 million in Placement - GlobeNewsWire
- 23 days ago - Alterity Therapeutics Announces Positive ATH434 Phase 2 Trial Results in Multiple System Atrophy Led By Robust Clinical Efficacy - GlobeNewsWire
- 4 weeks ago - Appendix 4C – Q2 FY25 Quarterly Cash Flow Report - GlobeNewsWire
- 6 weeks ago - Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming Milestones - GlobeNewsWire
- 2 months ago - Alterity Therapeutics Completes Last Patient Visit in ATH434-201 Phase 2 Clinical Trial in Early-Stage Multiple System Atrophy - GlobeNewsWire
- 3 months ago - Alterity Therapeutics Appoints Abby Macnish Niven as Company Secretary - GlobeNewsWire
- 3 months ago - Alterity Therapeutics Announces Presentation on Tracking the Progression of Multiple System Atrophy at International Symposium - GlobeNewsWire
- 3 months ago - Alterity Therapeutics Announces New Publication Describing Novel Mechanism of Action for ATH434 - GlobeNewsWire